Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

ImmunityBio (26CA) Stock Price & Analysis

19 Followers

26CA Stock Chart & Stats

€5.64-€0.37(-6.16%)
At close: 5:30 PM GMT+1
€6€7€8€9Aug 17Aug 28Sep 14Sep 30Oct 12Oct 26Nov 9
Day’s Range
EUR 5.60 - EUR 5.96
52-Week Range
EUR 1.68 - EUR 10.40
Previous Close
EUR 6.01
Volume
N/A
Average Volume (3M)
750
Market Cap
EUR 6.41B
Enterprise Value
EUR 10.97B
Total Cash (Recent Filing)
EUR 334.33M
Total Debt (Recent Filing)
EUR 869.52M
Price to Earnings (P/E)
―
Beta
0.93
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
-0.12
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Rapid Revenue Scaling And High Gross Margin

Rapid revenue expansion combined with an exceptionally high gross margin indicates strong initial product economics and growing commercial adoption. If the company can control operating costs as sales scale, this revenue base could provide meaningful operating leverage and support reinvestment in additional indications.

Expanded ANKTIVA Addressable Market

The FDA label expansion materially broadens the eligible patient population for ANKTIVA plus BCG, particularly by including papillary-only disease. A wider label strengthens the product’s commercial runway, improves physician relevance, and creates a more durable foundation for adoption in bladder-preserving care.

Positive Randomized Trial Efficacy Evidence

Meeting the primary endpoint in a randomized 370-patient trial strengthens confidence in ANKTIVA’s efficacy beyond the existing approval. Consistent safety, maintained quality of life, and an unreached median response duration could support broader physician adoption and future expansion in earlier-line bladder cancer.

Bears Say

Deep And Persistent Operating Losses

The company’s revenue growth has not yet translated into operating profitability, as expenses remain far ahead of sales and losses are worsening at the EBITDA level. Persistent losses may delay self-funded growth, reduce flexibility in commercial investment, and keep execution dependent on successful future scaling.

Negative Equity And Elevated Leverage

Negative shareholders’ equity and debt exceeding the asset base indicate substantial balance-sheet fragility. This structure leaves limited protection for investors and lenders, increases refinancing pressure, and could force the company to pursue dilutive financing if operating losses continue.

Ongoing Cash Burn And U.S. Concentration

Although operating cash burn improved from 2025, cash generation remains negative, so the business is not yet funding itself internally. Heavy reliance on U.S. growth adds another execution dependency: slower domestic adoption could constrain revenue progress while funding needs remain.

ImmunityBio News

26CA FAQ

What was ImmunityBio’s price range in the past 12 months?
ImmunityBio lowest stock price was €1.68 and its highest was €10.40 in the past 12 months.
What is ImmunityBio’s market cap?
ImmunityBio’s market cap is €6.41B.
When is ImmunityBio’s upcoming earnings report date?
ImmunityBio’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 108 days.
How were ImmunityBio’s earnings last quarter?
ImmunityBio released its earnings results on Nov 09, 2026. The company reported -€0.163 earnings per share for the quarter, missing the consensus estimate of -€0.063 by -€0.099.
Is ImmunityBio overvalued?
According to Wall Street analysts ImmunityBio’s price is currently Undervalued.
Does ImmunityBio pay dividends?
ImmunityBio does not currently pay dividends.
What is ImmunityBio’s EPS estimate?
ImmunityBio’s EPS estimate is -0.12.
How many shares outstanding does ImmunityBio have?
ImmunityBio has 1,063,826,000 shares outstanding.
What happened to ImmunityBio’s price movement after its last earnings report?
ImmunityBio reported an EPS of -€0.163 in its last earnings report, missing expectations of -€0.063. Following the earnings report the stock price went down -15.332%.
Which hedge fund is a major shareholder of ImmunityBio?
Hedge funds hold ImmunityBio shares: the largest hedge-fund position in ImmunityBio is 95,000,912 shares, and hedge funds decreased their holdings by 575.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology